Abstract:The effectiveness of commonly adopted therapeutic regimen is low for treating triple-negative breast cancer (TNBC), especially for inoperable patients at advanced stage. Herein, we reported a nano-based recipe for orthotopic and metastatic TNBC management by potentiating the deep penetration of antitumor agents in solid tumors and remodeling the tumor immune microenvironment through combinational chemoimmunotherapy. Specifically, doxorubicin (DOX) was loaded in DSPE-PEG2000-modified poly(amidoamine) (PAMAM) dendrimer to obtain small-sized DOX@P nanoparticles, which were further inserted into the phospholipid monolayer of imiquimod (R837)-encapsulated reconstituted high-density lipoprotein (rHDL) to acquire R@rHDP. Finally, M2 macrophage-targeting peptide (M2pep) was modified on the surface of R@rHDP to obtain R@rHDP-M2pep nanoparticles with special targeting ability towards M2-like tumor-associated macrophages (TAMs). Upon intravenous injection, R@rHDP-M2pep actively anchored TNBC sites owing to the natural tumor targeting potential of rHDL. Once reaching tumor sites, small-sized DOX@P was released from large-sized R@rHDP-M2pep due to the breakdown of imine bond in acidic tumor microenvironment (TME), further carrying DOX into the deep tumor core to exert chemotherapeutic effect. On the other hand, the remaining R@rH-M2pep continued to target M2-like TAMs to deliver R837 for effective polarization of TAM phenotype from protumoral M2-like into antitumoral M1-like type. Consequently, the immunosuppressive TME was remodeled to facilitate improved immunotherapeutic performance. Hence, the designed R@rHDP-M2pep nanoparticles displayed potent antitumor efficacy against TNBC, which not only remarkably suppressed orthotopic tumor growth, but also prevented the lethal lung metastasis of TNBC, largely prolonging the survival time of mice suffered from TNBC. Altogether, the proposed strategy exhibited promising research value in advancing the therapeutic protocols for TNBC.

A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.

Dual drug-loaded nano-platform for targeted cancer therapy: toward clinical therapeutic efficacy of multifunctionality

A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer

Multifunctional Nanosystem for Targeted and Controlled Delivery of Multiple Chemotherapeutic Agents for the Treatment of Drug-Resistant Breast Cancer

Reversing of Multidrug Resistance Breast Cancer by Co-Delivery of P-gp Sirna and Doxorubicin Via Folic Acid-Modified Core-Shell Nanomicelles

A Nanosized Codelivery System Based on Intracellular Stimuli-Triggered Dual-Drug Release for Multilevel Chemotherapy Amplification in Drug-Resistant Breast Cancer

Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based “combo” nanoagent together with PD-L1 blockade in reversing multidrug resistance

Theranostic micelles combined with multiple strategies to effectively overcome multidrug resistance.

Low-molecular-weight Protamine-Modified PLGA Nanoparticles for Overcoming Drug-Resistant Breast Cancer.

Platelet-camouflaged Nanococktail: Simultaneous Inhibition of Drug-Resistant Tumor Growth and Metastasis Via a Cancer Cells and Tumor Vasculature Dual-Targeting Strategy

Paclitaxel and Quercetin Co-Loaded Functional Mesoporous Silica Nanoparticles Overcoming Multidrug Resistance in Breast Cancer

Targeted Multidrug-Resistance Reversal In Tumor Based On Peg-Pll-Plga Polymer Nano Drug Delivery System

T7 peptide-mediated co-delivery platform overcoming multidrug-resistant breast cancer: In vitro and in vivo evaluation

pH- and photothermal-driven multistage delivery nanoplatform for overcoming cancer drug resistance.

Stimuli-sensitive Biomimetic Nanoparticles for the Inhibition of Breast Cancer Recurrence and Pulmonary Metastasis

Hyaluronidase-triggered Anticancer Drug and Sirna Delivery from Cascaded Targeting Nanoparticles for Drug-Resistant Breast Cancer Therapy

Dual-responsive Mpeg-Plga-pglu Hybrid-Core Nanoparticles with a High Drug Loading to Reverse the Multidrug Resistance of Breast Cancer: an in Vitro and in Vivo Evaluation.

Size-switchable and Dual-Targeting Nanomedicine for Cancer Chemoimmunotherapy by Potentiating Deep Tumor Penetration and Antitumor Immunity

cRGD-modified nanoparticles of multi-bioactive agent conjugate with pH-sensitive linkers and PD-L1 antagonist for integrative collaborative treatment of breast cancer

Dual-targeting Wnt and Upa Receptors Using Peptide Conjugated Ultra-Small Nanoparticle Drug Carriers Inhibited Cancer Stem-Cell Phenotype in Chemo-Resistant Breast Cancer

Coadministration of Chemotherapy and PI3K/Akt Pathway Treatment with Multistage Acidity/cathb Enzyme-Responsive Nanocarriers for Inhibiting the Metastasis of Breast Cancer.